252 related articles for article (PubMed ID: 26333348)
41. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
[TBL] [Abstract][Full Text] [Related]
42. Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease.
Collison A; Li J; Pereira de Siqueira A; Zhang J; Toop HD; Morris JC; Foster PS; Mattes J
Am J Respir Cell Mol Biol; 2014 Jul; 51(1):86-93. PubMed ID: 24484417
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
44. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
[TBL] [Abstract][Full Text] [Related]
45. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1.
Higuchi H; Grambihler A; Canbay A; Bronk SF; Gores GJ
J Biol Chem; 2004 Jan; 279(1):51-60. PubMed ID: 14561739
[TBL] [Abstract][Full Text] [Related]
46. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
[TBL] [Abstract][Full Text] [Related]
47. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.
Kamohara H; Matsuyama W; Shimozato O; Abe K; Galligan C; Hashimoto S; Matsushima K; Yoshimura T
Immunology; 2004 Feb; 111(2):186-94. PubMed ID: 15027904
[TBL] [Abstract][Full Text] [Related]
48. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
[TBL] [Abstract][Full Text] [Related]
49. Tissue distribution of the death ligand TRAIL and its receptors.
Spierings DC; de Vries EG; Vellenga E; van den Heuvel FA; Koornstra JJ; Wesseling J; Hollema H; de Jong S
J Histochem Cytochem; 2004 Jun; 52(6):821-31. PubMed ID: 15150291
[TBL] [Abstract][Full Text] [Related]
50. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
51. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
52. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.
Uberti D; Ferrari-Toninelli G; Bonini SA; Sarnico I; Benarese M; Pizzi M; Benussi L; Ghidoni R; Binetti G; Spano P; Facchetti F; Memo M
Neuropsychopharmacology; 2007 Apr; 32(4):872-80. PubMed ID: 16936710
[TBL] [Abstract][Full Text] [Related]
53. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
Eggert A; Grotzer MA; Zuzak TJ; Wiewrodt BR; Ho R; Ikegaki N; Brodeur GM
Cancer Res; 2001 Feb; 61(4):1314-9. PubMed ID: 11245427
[TBL] [Abstract][Full Text] [Related]
54. [Effects of puerarin on proliferation of vascular smooth muscle cells induced by thrombin].
Xu YZ; Wang NF; Li PZ; Wu X; Ling F; Zhang XW
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):476-80. PubMed ID: 16677576
[TBL] [Abstract][Full Text] [Related]
55. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
[TBL] [Abstract][Full Text] [Related]
57. Expression, regulation and function of trail in atherosclerosis.
Kavurma MM; Bennett MR
Biochem Pharmacol; 2008 Apr; 75(7):1441-50. PubMed ID: 18061141
[TBL] [Abstract][Full Text] [Related]
58. Naringin inhibits matrix metalloproteinase-9 expression and AKT phosphorylation in tumor necrosis factor-alpha-induced vascular smooth muscle cells.
Lee EJ; Kim DI; Kim WJ; Moon SK
Mol Nutr Food Res; 2009 Dec; 53(12):1582-91. PubMed ID: 19810018
[TBL] [Abstract][Full Text] [Related]
59. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
Higuchi H; Bronk SF; Taniai M; Canbay A; Gores GJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):461-7. PubMed ID: 12388624
[TBL] [Abstract][Full Text] [Related]
60. Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells.
Florean C; Schnekenburger M; Lee JY; Kim KR; Mazumder A; Song S; Kim JM; Grandjenette C; Kim JG; Yoon AY; Dicato M; Kim KW; Christov C; Han BW; Proksch P; Diederich M
Oncotarget; 2016 Apr; 7(17):24027-49. PubMed ID: 27006469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
